^
    Back
    Association details:
    Biomarker:MYC expression
    Cancer:Triple Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    dinaciclib (MK-7965) (CDK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2020
    Title:

    Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).

    Published date:
    05/13/2020
    Excerpt:
    Patients (pts) with advanced TNBC received dina IV day 1 and 8 in combination with fixed dose P 200 mg once every 21 days….MYC IHC staining on baseline metastatic tumor biopsies in 19 pts correlated significantly with clinical response….In exploratory analysis, greater MYC IHC staining correlated significantly with response to study therapy.
    DOI:
    10.1200/JCO.2020.38.15_suppl.1076
    Trial ID:
    B2151009